GILD trade ideas
GILD: need to break the $67 barrierwe're still holding GILD and now it's making another attempt at recovering from the recent drop
we need to break the $67 and stay above it for couple of sessions - with strong volume - to flag a proper recovery - the prior attempt for a breakout failed - this time there's some momentum and demand - but still light.
we'll see
Gilead sciences - long term investmentDear traders and followers,
It’s time again for one of our popular stock analytics. Today we take a closer look at Gilead Sciences
The California-based pharmaceutical and biotechnology company offers a very attractive mix of Corona’s special economy, a bit of takeover fantasy and a moderate evaluation. The drug Remdesivir, which is approved for Corona treatment, is expected to generate sales of almost two billion dollars this year, which according to Bloomberg’s 2021 estimate should increase by another 20 percent. The 2021 KGV of eleven is among the ten lowest in the entire Nasdaq 100. No wonder there is speculation that AstraZeneca wants to take over Gilead, given that both groups are complementary in their focus areas. If this is not enough as a reason to buy, the share traded around 40 percent below the record high looks at the nice lower reversal, which can be seen in the chart picture along with the medium-term upward trend.
Technical view:
Market has formed a triangle formation since 2014 (after a strong up rally) and broke out of it at the beginning of March. The price is atm within correction movement which is expected to end at the drawn buy area at around 70 $. We´ve set our buy orders at this point.
Feel free to leave a comment or to share your ideas in the comments section
Please hit the like button if you share or like this idea.
Thanks for your support !
Swing trade idea on Gilead SciencesI don't actually like Gilead Sciences for a long-term buy and hold, because its earnings have been in a long-term downtrend. There's a case to be made for a swing trade, however. Gilead is now sitting on trend line support in a fairly high-volume range. It's about 25% below its median forward P/E and forward P/S for the last three years. It has been selling off on news that remdesivir has shown no therapeutic value for Covid-19, but it may now rally for a while on news that the FDA has approved it for emergency use in moderate Covid patients anyway.
GIILD 12.08.20 LongAsset and Time frame -GILD,4H
Entry Price -68.99
Exit(Stop Loss) -67.19
Exit(Take Profit) -75.55
Technical Analysis -Price reacted to the -27.2 for the second time(less favorable) but had a hard time going even more downwards, on the 4H chart price has left the tunnel with a gap up, on weekly chart price is sitting on the 100SMA, also RSI divergence
What can be improved -
Conclusion & End of Trade -
GIILD 05.08.20 LongAsset and Time frame - Daily
Entry Price -70.88
Exit(Stop Loss) -68.13
Exit(Take Profit) -80.41
Technical Analysis -On the daily chart price reacted to the -27.2 level with an engulfing bullish candle, on the weekly chart theres the 100MA being used as support, and on the 4 hours price reached the -61.8 level
What can be improved -
Conclusion & End of Trade -
GILEAD BUYGilead is giving a re entry point here.
AT:
Price its un compressing , has break the trendLine giving us a good RR entry.
Fundamentals:
July 22 is the earning report ,the US government has purchased all available stock of the remdesivir vaccine.
Enjoy profits , and don't forget to follow us for more ! :D
Bullish Charts - COVID-19 VaccineGilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
On 07/11/20, Gilead announced its drug Remdesivir can reduce risk of death in COVID-19 patients.
On 07/10/20, Former FDA Commissioner Scott Gottlieb said Remdesivir data showed improved COVID-19 Recovery & Reduced Risk of Death by 62%.
The COVID-19 drug alone could be a huge revenue boom for Gilead into the future as many countries stockpile & use it.
On the Daily Chart, it looks to me like a Pennant has formed with a breakout coming, Bullish
Volume, Bullish
PMO, Bullish
MACD, Bullish
RSI, Bullish
OBV, Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
